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Vitamin D has a plethora of functions that are important for the maintenance of general 
health and in particular, the functional integrity of the immune system, such as pro-
moting an anti-inflammatory cytokine profile and reducing the Treg/Th17 ratio. Multiple 
sclerosis (MS) is a chronic, inflammatory, and neurodegenerative central nervous system 
(CNS) disorder of probable autoimmune origin. MS is characterized by recurring or 
progressive demyelination and degeneration of the CNS due in part to a misguided 
immune response to as yet undefined (CNS) antigens, potentially including myelin basic 
protein and proteolipid protein. MS has also been shown to be associated significantly 
with environmental factors such as the lack of vitamin D. The role of vitamin D in the 
pathogenesis and progression of MS is complex. Recent genetic studies have shown 
that various common MS-associated risk-single-nucleotide polymorphisms (SNPs) are 
located within or in the vicinity of genes associated with the complex metabolism of 
vitamin D. The functional aspects of these genetic associations may be explained either 
by a direct SNP-associated loss- or gain-of-function in a vitamin D-associated gene or 
due to a change in the regulation of gene expression in certain immune cell types. The 
development of new genetic tools using next-generation sequencing: e.g., chromatin 
immunoprecipitation sequencing (ChIP-seq) and the accompanying rapid progress of 
epigenomics has made it possible to recognize that the association between vitamin 
D and MS could be based on the extensive and characteristic genomic binding of the 
vitamin D receptor (VDR). Therefore, it is important to analyze comprehensively the spa-
tiotemporal VDR binding patterns that have been identified using ChIP-seq in multiple 
immune cell types to reveal an integral profile of genomic VDR interaction. In summary, 
the aim of this review is to connect genomic effects vitamin D has on immune cells with 
MS and thus, to contribute to a better understanding of the influence of vitamin D on the 
etiology and the pathogenesis of this complex autoimmune disease.
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iNTRODUCTiON
Vitamin D was named as the fourth factor identified in an experimental rickets model (1). The 
role of sunlight in the synthesis of this factor had been recognized in unrelated research but had 
initially not been understood in the context of this factor now termed vitamin D (2). Further 
research on the constitution of sterols and their connection to vitamins resulted in the Nobel 
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price for Chemistry in 1928 for Adolf Windaus (3). Finally, 
the biochemical pathway in its entirety and the connection to 
sunlight was published in 1955 (4) and summarized in more 
detail 25 years later (5).
The nomenclature of vitamin D and its metabolites has been 
well defined by Vieth, and for the purpose of this review we will 
use their terminology to refer to the level of serum 25 hydroxy 
vitamin D [25(OH)D] the major circulating form of vitamin 
D that is often used to define vitamin D status (6). For in vitro 
experiments, we use 25(OH)D3 and 1,25(OH)2D3 according to 
the quoted work.
As an important environmental factor, vitamin D deficiency 
has been associated with increased multiple sclerosis (MS) 
risk (7, 8), a finding that has been supported genetically by a 
Mendelian Randomization analysis of vitamin D-associated 
single-nucleotide polymorphisms (SNPs) (9, 10). Moreover, 
multiple factors that affect vitamin D status including ultravio-
let B radiation exposure (UVR), latitude, systemic infection, 
and smoking, are associated with MS risk, and higher levels of 
serum 25(OH)D have a protective effect on MS risk but not on 
the clinical course or the severity of MS (11). Although clinical 
trials of vitamin D supplementation with the primary outcome 
being MS risk have not been undertaken due to their complex-
ity, the need for many years of follow-up and the overall low 
risk of MS in the general population there is a considerable 
body of research regarding the protective effect of vitamin D 
status on MS clinical activity, such as a decrease in magnetic 
resonance imaging lesions (12) and a reduced hazard of relapse 
(13). Since MS is a chronic, inflammatory, autoimmune disease 
that could potentially originate from an autoimmune response 
to neurodegenerative central nervous system (CNS) antigens 
such as protein components of the myelin sheath (14) with 
periods of de- and remyelination or progressive demyelination 
driven by a strong involvement of various branches of the 
immune system (15) an effect of vitamin D metabolites on the 
overall inflammatory state within the CNS would be a logical 
explanation (11).
Furthermore, besides the obvious impact of a deficiency due 
to environmental factors, genetic aspects of control over the vita-
min D metabolism appear to be also important. In total, more 
than 200 common risk SNPs have been found in genome-wide 
association studies (GWAS) outside the HLA region that are 
significantly associated with MS (16). Among these common risk 
SNPs [published in the NHGRI GWAS Catalog (https://www.
ebi.ac.uk/gwas/search?query=MULTIPLE%20SCLEROSIS) and 
IMSGS (16)], there are several that are linked with vitamin D 
metabolism-associated genes. CYP24A1, rs2248137 (16), and 
rs2248359 (17), and SNPs that tag a chromosome 12 linkage 
disequilibrium (LD) block that contains the gene CYP27B1, 
rs12368653/rs703842/rs10876994 (17, 18), rs201202118 (19), 
and rs701006 (16). Some rare risk SNPs have been identified in 
vitamin D metabolism genes, such as rs118204009 in CYP27B1 
(20) although this has not been confirmed in subsequent work 
(21), and rs117913124 in CYP2R1 (22), which may impact both 
the risk of vitamin D insufficiency and the risk to develop MS, 
a validation of these findings in other cohorts will be necessary. 
However, the cross sectional case–control design of GWAS that 
define risk is by their nature not suitable for predicting clinical 
course. All known genes identified by GWAS including those 
identified in the HLA region have not shown a significant 
association with the clinical course of MS in the GWAS stud-
ies themselves. Some associations with MS clinical course have 
been found when these SNPs are used as candidate genes in 
longitudinal MS studies focusing on clinical severity and disease 
course (23–26) suggesting that genetic variants that tag the Vit 
D pathway genes have a functional impact on the clinical course 
of MS (27, 28).
A second major aspect of the role of vitamin D in the etiology 
of MS are the extensive genomic binding regions of the nuclear 
vitamin D receptor (VDR), which is the only cognate receptor 
of the active form of vitamin D [1,25(OH)2D3 or calcitriol]. 
It acts as a transcription factor (TF) that interacts with multiple 
other TFs and coregulators, and binds to regulatory hotspots 
throughout the genome (29, 30). In fact, many enhancers that 
contain VDR-binding sites are located within regulatory hubs 
of enhancers [so-called super-enhancers (SEs)] which are now 
considered to be involved in the regulation of cell fate (cell 
identity or cell differentiation) (29, 31). The large number of 
genes containing VDR-binding sites is probably one mechanism 
that allows organisms to integrate environmental stimuli into 
functional effects which can influence for example, cell differ-
entiation (30, 32–34).
In this review, we try to connect the genomic effects of vitamin 
D on immune cells with MS etiology by discussing the cistrome 
of the VDR. First, we will discuss the effects of vitamin D on 
immune cells and the implications of GWAS results that indicate 
vitamin D-associated genes are involved in the immune response. 
Furthermore, we will review the cistrome of the VDR in multiple 
immune cells. The association of the VDR cistrome with epig-
enomic characteristics, including SE regions, in these cells, could 
help to analyze the potential mechanisms underlying the role of 
vitamin D in MS etiology and pathogenesis.
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THe iNFLUeNCe OF viTAMiN D AND  
iTS COMPLeX MeTABOLiSM ON MS
immunological effects Underlying the  
Role of vitamin D As an environmental 
Factor for MS
The early stages of MS are assumed to be mediated by activated 
CD4+ T  cells that express pro-inflammatory cytokines and 
faci litate chronic inflammation that causes demyelination. Origi-
nally, the concept of an ill-timed transition from the Th1 to Th2 
state was considered to be a major contributing factor for the 
development of autoimmune disease (35). However, new, more 
detailed studies that have investigated the roles of newly defined 
T  cell subsets under the extended T  cell paradigm point to an 
imbalance of Th17 and Treg populations as an underlying factor 
for the development of multiple autoimmune diseases (36–39).
The active form 1,25(OH)2D3 has been implicated previously 
in Th1/Th2 conversion and now in Th17/Treg balance (40, 41). 
Specifically, 1,25(OH)2D3 can inhibit the Th17 phenotype by 
inhibiting the transcription of RORγt, IL-17, IL-23R, and IL-22 
(42), and promote the Treg subset by inducing the expression of 
IL-10, Foxp3, and CTLA-4 (43, 44). Furthermore, 1,25(OH)2D3 
can also inhibit the expression of IL-2 and IFN-γ and modulate 
differentiation of Th17  cells (45, 46). Granulocyte/mac-
rophage colony-stimulating factor (GM-CSF) secretion, as an 
emerging risk factor for MS, is also inhibited by 1,25(OH)2D3  
(36, 47). In addition, the expression of the Th17 marker mol-
ecule CCR6 is reduced by 1,25(OH)2D3, which in turn, reduces 
the number of Th17 cells migrating in response to CCL20 to 
the central nervous system (48). Furthermore, 1,25(OH)2D3 
also inhibits the proliferation of isolated CD4+ T  cells and 
myelin basic protein (MBP)-specific T cells from MS patients 
in vitro (49).
In addition to changes in the Th subset ratio, other immune 
cell subsets also potentially play roles in MS pathology, which 
can be aligned with or complement T cell-centered pathology. 
Pro-inflammatory T  cells can recruit B  cells, myeloid cells 
[monocytes/dendritic cells (DCs)], natural killer (NK) cells, or 
CNS-resident macrophages (microglia) to the pathology. They 
can interact and, for example, induce complement depositions 
and cause opsonization and local activation of microglia and 
macrophages until demyelination occurs (50). As immuno-
globulin G1 and myelin reactive antibodies are identified in the 
cerebrospinal fluid of MS patients, B cells may contribute to MS 
pathogenesis via their ability of antigen presentation or produc-
tion of immunoglobulins (50). Pro-inflammatory CD14+CD16+ 
monocytes show activation in MS patients, and their ability to 
disrupt the blood–brain barrier also is contributing to MS pathol-
ogy. Monocyte differentiation can lead to opposite functionality 
in macrophages depending on the cytokine environment: 
either pro-inflammatory M1- (or DC1) or anti-inflammatory 
M2-macrophages (or tolerogenic DC2) (51, 52). NK  cells can 
migrate into CNS and can display various functions. They can 
show cytotoxicity to DCs suggesting a pathological role in MS. 
Counterintuitively, their number and functional activity is 
reduced in MS patients (50).
By analysis of gene expression patterns (such as RT-PCR and 
RNA-seq) or epigenomic features [such as chromatin immuno-
precipitation sequencing (ChIP-seq) and DNase hypersensitivity 
sites], all immune cells (including microglia) and neuron cells 
partly express MS risk genes (16, 53, 54), but MS risk SNPs are 
preferentially more enriched in the SE region of CD4+ T  cells, 
than in that of B  cells and monocytes (32, 33). Interestingly, 
ChIP-seq results showed a stronger sensitivity of MS risk genes 
detecting 121 distinct genes with VDR binding peaks in DC2s 
whereas RNA-seq identified only one differently expressed gene 
in DC2s compared with the transcriptome of DC1s or monocytes 
(53). Supporting the notion that vitamin D has a biological role 
in CNS autoimmunity, all these cell types can be impacted by 
1,25(OH)2D3. For example, 1,25(OH)2D3 inhibits proliferation, 
plasma cell differentiation and antibody production of B  cells, 
but promotes class-switched memory B cell generation and B cell 
apoptosis (55). Furthermore, via inhibiting cell differentiation 
1,25(OH)2D3 could be involved in preserving the immature status 
of DC with considerable ramifications for the specific immune 
response. This cell population has in its immature form charac-
teristics such as lower expression of MHC class II, costimulatory 
molecules and IL-2, which could lead to a modulation of antigen 
presentation and ultimately, self-tolerance (55).
In the context of these vitamin D functions the still unresolved 
question of the required, physiologically effective concentration 
of 1,25(OH)2D3 should be mentioned as a caveat. The concen-
trations employed in in  vitro experiments (10–100  nM) or the 
physiologically effective concentrations observed in the in vivo 
microenvironment (1–10  nM) can actually be produced in 
both autocrine or paracrine pathways by DCs or T cells via the 
hydroxylation of 25(OH)D (which has on average a physiological 
concentration in the blood of 50–80  nM), to 1,25(OH)2D3 by 
the enzyme 25-hydroxyvitamin D3 1α-hydroxylase (CYP27B1) 
(43, 46, 56). Notably, concentrations of either 10−6 or 10−7  M 
of 1,25(OH)2D3 will induce either Foxp3 or IL-10 expression, 
respectively, with little co-expression (44). This suggests that a 
precise control of the local vitamin D concentration needs to be in 
place in the microenvironment to achieve homeostasis. How this 
is approached physiologically is not understood. Actually, under 
in  vivo conditions a small rise (~10  nM) in 25(OH)D3 serum 
levels can lead to significant changes at hundreds of sites within 
the epigenome of human leukocytes (57).
The complexity of the interactions between vitamin D and 
the immune system have been demonstrated in more detail in 
mouse models. In experimental autoimmune encephalomy-
elitis (EAE), a model of neuroinflammation used to study MS, 
vitamin D treatment ameliorated the clinical symptoms of EAE 
mice. Reciprocal bone marrow chimeras using VDR-knockout 
(VDR-KO) bone marrow showed that the hematopoietic donor 
cells needed to have a functional VDR to cause this attenuation 
of the pathology. Interestingly, no change in the total number of 
CD4+ T cells or the proportion of Foxp3+ T-cells in the periphery 
or the CNS could be detected (58). By contrast, in a model of 
inflammatory bowel disease either in VDR-KO mice or in the 
absence of vitamin D an overproduction of Th17  cells and a 
reduction of inducible Tregs could be shown (59). Addition of 
vitamin D reversed this effect in T cell culture (59) and in an 
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in  vivo model (60). In a dextran sodium sulfate colitis model, 
VDR-KO mice showed increased sensitivity and early mortality 
which could be ameliorated with 1,25(OH)2D3 (61). However, 
ultimately a T  cell-specific VDR-KO model will have to be 
employed to confirm these observations. Furthermore, VDR-KO 
mice have an impaired resistance to allergic asthma, support-
ing the notion of a suppressive effect of VDR absence on Th2 
responses (62). Controversially, it has also been described that 
less Th2-cytokines IL-4, -5, and -13 are produced by VDR-KO 
Th2 cells (63), and vitamin D can inhibit the allergic asthma phe-
notype (64). Furthermore, gene conservation between primates 
and rodents needs to be considered. For example, VDR target 
genes encoding AMPs human beta-defensin 2 and cathelicidin 
(CAMP) and the pattern recognition receptor NOD2 are only 
induced in human cells after 1,25(OH)2D treatment, but not in 
mouse cells (65).
The immunoregulatory effects of vitamin D on the human 
immune system will be more complex, as a result of synergis-
tic/antagonistic effects of various environmental factors with 
vitamin D, and dose-/time-dependency in vivo. A multitude of 
clinical translational studies, in part double-blinded randomized 
controlled trials on clinically isolated syndrome or relapse-
remitting multiple sclerosis (RRMS) MS patients, has attempted 
to analyze the role of vitamin D. It has been a consistent result 
that serum 25(OH)D level and TGF-β level will increase after 
vitamin D supplement of either 1,000  IU/day for 6  months 
(66), or 20,000 IU/week for 48 weeks (supplementing IFNβ-1b 
therapy) (67), although one study (7,000  IU/day for 4  weeks 
followed by 14,000 IU/day for 44 weeks in addition to IFNβ-1a 
therapy) only observed an increased serum TGF-β level in the 
placebo group rather than the vitamin D group (68). However, 
most studies have not been able to reveal an immunoregula-
tory effect of vitamin D on serum cytokine profile and immune 
cell subsets (66, 67, 69–72). This could indicate that there is 
no correlation between the higher serum 25(OH)D level and 
pro-inflammatory cytokine/chemokine profiles (39). One study 
observed a reduced proportion of CD25+ Tregs and decreased 
circulating soluble-CD25 only in placebo group, suggesting 
a maintenance effect of vitamin D on immune homeostasis 
(73). Other studies also found a reduced IL4+ Th cell propor-
tion in the placebo group (68), and the IFN-γ/IL-4 ratio (Th1/
Th2-balance) was more directed toward IL-4 in patients with 
increased serum 25(OH)D levels (74). This would suggest an 
anti-inflammatory effect of vitamin D. Among those studies, a 
proposed dose-dependency is reflected in high-dose 10,400 IU/
day vitamin D treatment for 6 months will increase 25(OH)D 
level more strongly and can alter the proportion of CD4+ T cell 
subsets (i.e., reduced IL-17+ Th/CD161+ Th/effector memory 
Th cells, increased central memory Th/naive Th cells) in RRMS 
patient is compared with 800  IU/day (75). Similarly, 800  IU/
day vitamin D treatment for 1  year will induce more serum 
IL-17 in RRMS patients, while patients with high-dose 4,370 
IU/day treatment only showed heterogeneous IL-17 response 
(70). Concurrently, a time-dependency of vitamin D treatment 
is demonstrated by reduced anti-EBNA1 protein and fragment 
antibody levels from baseline to week 48 but not to week 96 of 
the therapy (76).
Interestingly, some MS-specific changes that can not be 
observed directly ex vivo can be found after PBMCs culture 
in vitro. For example, in tissue culture the GM-CSF secretion of 
CD4+ T cells from MS patients was less reduced by vitamin D 
than in healthy controls (77). In addition, the serum 25(OH)D 
levels from RRMS patients correlated positively with the ability 
of Treg cells to inhibit T  cell proliferation (74). Likewise, for 
PBMCs from MS patients with vitamin D supplement, their 
in  vitro proliferative responses to antigens such as MBP were 
reduced (69). Similarly, in  vitro PBMCs proliferation in the 
vitamin D supplement MS group were significantly reduced, 
and the supernatant levels of TGF-β and IL-10 were increased, 
compared with that in the placebo MS group (78). In considera-
tion of the complexity of vitamin D supplement effects in vivo, 
more RCT trials with higher statistical power have to be carried 
out to avoid heterogeneity among participants and different 
centers. This can be supplemented by Real-World data, such 
as patient-reported outcomes or associated epidemiology data 
(79). On the other hand, analyses of genomic effects of vitamin 
D and its associated genes in different cell types could provide 
a more reductionistic explanation of confusing results from 
translational researches.
Potential Mechanism of vitamin 
D-Associated Metabolic enzymes in MS
The immune cell types discussed earlier such as T cells (49, 56, 
80–83), B  cells (84, 85), DCs (86–89), macrophages (87), and 
CNS cells, such as neurons, microglias, astrocytes, and invad-
ing lymphocytes (90–92), can express CYP27B1 and CYP24A1, 
according to their environmental status and during different cell 
stages. Interestingly, these genes are under precise regulation as 
a result of integrating environmental factors and interactions 
among different cell types. For example, after 24 h activation of 
T cells, the 1,25(OH)2D3 production from 25(OH)D3 is very low, 
but it strongly increases after 48 h of activation (82). Therefore, 
after only 24 h activation, some investigations cannot observe the 
capacity of CD4+ T cells for converting 25(OH)D3 to 1,25(OH)2D3 
(56). Under normal physiological conditions, inactivated T cells 
lack 1α-hydroxylase protein, and the function of the CYP27B1 
enzyme will be provided by APCs in close contact (52, 56). 
Furthermore, activated T cells that interact with macrophages will 
increase the CYP27B1 expression in macrophages, an effect that 
is similar to the treatment of macrophages with IFN-γ or soluble 
CD40L. In fact, multiple environmental factors and cell signals 
impact the regulatory network of CYP27B1 and CYP24A1 and 
change their expression level, such as 1,25(OH)2D3/VDR itself, 
parathyroid hormone (PTH)/prostaglandin/PKA, Ca /2+ PKC , 
TCR/Zap-70, and various other cell differentiation signals 
(41, 56, 80, 82, 83, 88, 93). For example, the binding of STAT1 to 
VDR which is induced by IFN-γ prevents the CYP24A1 expres-
sion in monocytes and macrophages (94). But Th cell-produced 
IFN-γ can promote the TLR2/1 induced expression of CYP27B1 
and VDR in monocytes, while IL-4 has been shown to be inhibi-
tory and instead induces CYP24A1 expression (95). Furthermore, 
through binding to VDR, 1,25(OH)2D3 can downregulate its 
own production by decreasing the expression of CYP27B1 and 
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increasing the expression of CYP24A1 (96–98). In addition, VDR 
can also regulate its own expression, and thus, the metabolism 
of vitamin D via binding vitamin D responsive elements in the 
enhancer/promoter regions of VDR/CYP24A1/CYP27B1 genes 
(99, 100). During the process, epigenetic mechanisms partici-
pate in the regulation of VDR expression, such as methylation 
of VDR promoter, acetylation of histone 4 in VDR enhancers, 
and levels of miR-125b (101). All these studies have revealed a 
complex regulatory network of CYP27B1/CYP24A1 with differ-
ent requirements in different cell types, although, interestingly, 
in vitro myeloid cells express higher levels of CYP27B1/CYP24A1 
without further stimulation (52, 53).
It has been attempted to isolate the potential functions of MS 
risk SNPs by identifying MS risk genes (with or in proximity to 
MS risk SNPs) that are associated with heritable altered ratios or 
responsiveness of immune cells subsets from MS patients (54). 
Many genes that are stably expressed in certain immune cell 
subsets and have been identified as potential MS risk genes from 
cohort studies, direct immune cell differentiation in MS patients 
such as NF-κB in PBMCs (102), IL2RA in GM-CSF+ memory Th 
cells (103), TYK2 (tyrosine kinase 2) in Th2 cells (104), EOMES/
TBX21 in CD56+ NK  cells (105), and ZMIZ1 in plasmacytoid 
DCs (106). However, the mechanisms how those genes with risk 
alleles affect the responsiveness or differentiation of immune 
cell subsets are still unclear. For example, questions how IL2RA 
with risk allele alters IL-2 responsiveness of naive Th cells and 
deviates their differentiation into GM-CSF-producing memory 
Th cells. How IL2RA polymorphism impacts IL-2/STAT5 signal-
ing pathway? IL2RA gene actually has a high ranking SE region 
in all Th1/Th2/Th17 cells, with potentially extensive regulatory 
function (33). How TYK2 polymorphism regulates T lymphocyte 
differentiation toward a Th2 phenotype and what the functions of 
EOMES/TBX21 gene sets in CD56+ cell and ZIMZ1 sets in plas-
macytoid DCs of MS patients are. Could there be a robust uni-
fied underlying mechanism that affects a common key genomic 
structure involved in cell fate determination? We will discuss the 
influence of the vitamin D status in genomic regions as a key to 
these questions in the second part of this review.
In support of a role of vitamin D, MS-associated SNPs that have 
been identified in recent GWAS results are located around the 
vitamin D metabolism-associated genes CYP27B1 and CYP24A1, 
and they have a modest but significant regulatory effect on gene 
expression in certain cell types.
The gene CYP27B1 encodes 25-hydroxyvitamin D3 
1-alpha-hydroxylase, an enzyme that converts 25(OH)D by 
hydroxylation to 1,25(OH)2D3. This hydroxylase forms part of 
an LD group on chromosome 12 and the major alleles of SNPs 
rs10877012 (G), rs10877013 (C), and rs703842 (A) (tagged by 
SNP rs6581155 with r2 ≥ 0.8) identify the CYP27B1 haplotype 
associated with an increased risk of MS (52, 107). It has been 
shown in vitro that this haplotype of CYP27B1 is downregulated 
in tolerizing DC which could point to a role in an autoim-
mune pathology (52). And lower CYP27B1 mRNA expression 
was associated with rs10877013 (C) in LPS  +  IFNγ-treated 
monocytes (108). Unfortunately, another member of this LD 
METT21B (previously termed FAM119B) has been shown to 
be similarly regulated in the same cell types no matter its gene 
expression from qPCR or its multiple isoforms from RNA-seq, 
which prevents a clear conclusion (52). In an unrelated study 
METT21B mRNA has been shown to be downregulated in cells 
isolated from whole blood samples (109). However, according 
to mRNA data from immortalized peripheral lymphocytes, 
the expression of METTL1, CYP27B1, and CDK4 are all 
regulated by rs10876994, rs12368653, or rs703842 (110). Using 
a comprehensive approach [expression quantitative trait loci 
(eQTL), ENCODE annotation, and luciferase reporter assay], 
it has been indicated that the SNP rs10877013 can regulate the 
enhancer activity and the gene expression of the LD region 
(increasing the expression of TSFM/TSPAN31, reducing the 
expression of CYP27B1/METT21B/AVIL) in a allele-dependent 
and orientation-dependent way, by interfering with CCAAT/
enhancer-binding protein (C/EBP) α and β binding and engag-
ing promoter–enhancer/promoter–promoter interaction loops 
(107). Interestingly, C/EBP β can determine adipocyte differ-
entiation at early stage by interacting with other TFs (including 
VDR) in a TF binding hotspot on chromatin (30). And there are 
multiple isoforms for METT21B and TSFM in DC2s, suggest-
ing a potential association of the region with long non-coding 
RNA transcription (111) and further SE regions (112). But in 
the immune system, the relationship between haplotype and cell 
fate determination needs further analysis. A second risk SNP 
(rs2248359 located separately from the chromosome 12 LD) that 
has been identified in the same GWAS as MS-associated tags the 
gene CYP24A1 that encodes for the enzyme 1,25-dihydroxyvita-
min D3 24-hydroxylase which can deactivate 1,25(OH)2D3 (17). 
The MS risk allele rs2248359-C increases CYP24A1 expression 
in the frontal cortex but not in white matter of the human brain 
(92). This enzyme was also present in DC and 1,25(OH)2D3-
simulated B cells but without a difference between two alleles 
in tolerizing/pro-inflammatory DC and B cell (52, 108). Taken 
together, the specific mechanism of how these risk SNPs func-
tion in different cell types and contribute to the regulation of 
gene expression and then the etiology of MS is still unclear as are 
their possible multiple indirect effects on distant genes or long-
term effects amplified by other risk factors during cell activation. 
It is conceivable that one SNP can impact multiple transcription 
processes in certain cell type at certain developmental stage 
within some basic important chromatin structures, such as SE.
ReGULATORY MeCHANiSM OF  
vDR iN MS
vDR Binding to Chromatin and  
its Association with MS
There are only a limited number of studies about the general 
effects of VDR binding to VDR binding sites in the genome on 
the shape of the transcriptome. VDR belongs to the superfamily 
of nuclear receptors and is located mainly in the cytoplasm. After 
binding its cognate ligand 1,25(OH)2D3 VDR recruits its partner 
retinoid X receptor (RXR) and can now translocate from the 
cytoplasm to the nucleus and engage target genes via binding to 
its genomic binding sites (113–115). It interacts with TF and/or 
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coregulators. And it binds to cell type-specific VDR binding sites. 
The association between extensive VDR binding and MS is sup-
ported by the overlapping localization of VDR ChIP-seq intervals 
and MS risk SNP regions (53, 116–118).
The Interaction between VDR and TFs/Coregulators
In in  silico motif analysis of experimentally determined VDR 
binding sites by ChIP-seq identified that the majority of VDR 
binding sites did not have canonical VDR binding motifs, which 
consist of a direct repeat of two hexameric core binding motifs 
with a spacing by 3 nucleotides (DR3), even though they are 
enriched for DR3 motifs compared with the genomic back-
ground (53, 119, 120). Therefore, to allow DNA binding and the 
regulation of transcription directly or indirectly, it is mandatory 
that VDR can form complexes in association with other TFs or 
coregulators. First, VDR can modify its DNA location by inter-
acting initially with other TFs. Examples are the TF PU.1 (for 
monocyte/macrophage and B  cell differentiation), STAT5 (for 
cytokine signaling in T  cell activation), DNA-binding subunit 
of GABP (GABPA) in THP-1 cells, with motifs that have been 
found within the peaks of VDR/RXR binding (119–121). The 
co-localization of GABPA and VDR has been confirmed by 
ChIP-seq data of GABPA cistrome, which can further interact 
with PU.1 for regulating genes in cellular and immune signaling 
processes (122). Six MS risk genes expressed by myeloid cells 
(monocyte/DC1/DC2) have also been found co-localized with 
VDR (both with VDR binding region and canonical VDR motif) 
(53). One motif of the MS risk gene BATF is highly represented 
in VDR binding peaks of DC1s and DC2s (53), suggesting a 
potential association between DC and Th17, and a role of VDR 
in their differentiation (123). Furthermore, sixteen DC1-specific 
MS risk TF genes, which are only represented in VDR binding 
peaks of DC1s but not of DC2s/monocytes, are enriched for IL-1 
(p = 2.6 × 10−6)/IL-6 (p = 6.1 × 10−9)/MIF (p = 9.2 × 10−5) (not 
corrected for multiple testing) signaling pathways associated 
with inflammation (53). By analyzing ChIP-seq data both from 
VDR and PU.1, PU.1-VDR cross talk has been demonstrated in 
open chromatin in 1,25(OH)2D3-sensitive PU.1 loci which were 
closer to the 1,25(OH)2D3 target genes (124). It could also be 
shown by integrating VDR ChIP-seq data and GWAS results that 
only 2 of 42 identified trait/disease risk SNPs resided within a 
canonical VDR-binding site, and 33% of the 42 SNPs impacted 
the immune-related binding and gene regulation by other TFs 
including NF-κB. The co-enrichment of VDR and NF-κB bind-
ing in CEPH cell lines suggested the cross talk between VDR 
and NF-κB (118). In human CD4+ cells, VDR binding intervals 
are enriched for CCCTC-binding factor (CTCF) motifs (125), 
which is an architectural protein at the borders of topologically 
associated domains (TAD). In monocyte, 1,25(OH)2D3 -depend-
ent CTCF binding sites also partly overlap with VDR binding 
regions and contribute to DNA looping/TAD shaping (126). 
VDR/RXR and TF 4/β-catenin can also interact and bind one 
distal enhancer region to regulate c-FOS and c-MYC gene 
expression in colonic cells, which occurs in a ligand-dependent 
manner (127).
Second, VDR has also been shown to bind VDR coregulators, 
which do not directly interact with DNA but are associated with 
the regulation of gene expression by their modulation of the 
DNA superstructure such as helicase, histone acetyltransferase, 
proteasome-dependent proteolysis, histone deacetylase, etc. 
(113). For example, VDR can recruit histone acetyltransferase 
to activate transcription (128) and bind nuclear receptor co-
repressor 1/2 to recruit histone deacetylase which suppresses 
transcription via chromatin modification (113). And in LS180 
(human colon adenocarcinoma) cells, VDR co-localize with 
many other coregulators for regulating regulated 1,25(OH)2D3 
responsive genes (129).
Engaging VDR Binding Region and Enhancers
The main DNA regions bound by VDR are enhancers indicating 
that this nuclear receptor acts with a strong tissue specificity. 
The observation of autoregulation of VDR on the VDR gene, 
has supported the notion that VDR/RXR can bind the S1, S3 
and U1 enhancers in the VDR gene regulating its own tran-
scription in a tissue-specific manner (99, 130). The regulation 
of VDR depends on epigenetic modification (101). For exam-
ple, hypermethylation of VDR promoter and deacetylation of 
histone H4 in VDR enhancers will reduce the transcription 
of VDR gene. High levels of miR-125b posttranscriptionally 
downregulate VDR mRNA levels. Furthermore, coregulatory 
factors such as RNA polymerase II, cAMP response element-
binding factor (CREB), glucocorticoid receptor, C/EBPβ, and 
Runt-related transcription factor 2 can be recruited to regulate 
VDR expression after ligand-dependent epigenetic modifica-
tion, such as histone H4 acetylation (99). This suggests that 
these VDR-specific enhancers can integrate signals from mul-
tiple environmental factors (e.g., vitamin D, glucocorticoids, 
retinoid acid, and PTH) by interacting with their associated 
TFs (99, 130). This is also the case for a central metabolic 
enzyme of the vitamin D pathway, 1,25(OH)2D3 24-hydroxy-
lase or CYP24A1. In the case of this enzyme, the presence of 
1,25(OH)2D3 strongly induces the simultaneous presence of 
VDR and RXR. After translocation to the nucleus the VDR 
complex binds to VDR binding sites at the promoter regions 
of CYP24A1 and to a cluster of enhancers located in intergenic 
regions downstream of the enzyme upregulating its expression. 
In this case, the recruitment of coregulators steroid receptor 
coactivator 1, mediator complex subunit 1 (MED1), silencing 
mediator of retinoid and thyroid hormone receptor, and the 
occurrence of histone H4 acetylation are all associated with the 
VDR/RXR binding (17, 131, 132).
With the development of ChIP-seq, which represents an 
unbiased method that can quantify binding of a specific pro-
tein to certain DNA sequences, it is possible to determine the 
genome-wide extent of the binding of a specific TF to DNA. In 
a B  cell-derived lymphoblastoid cell line (LCL), 1,25(OH)2D3-
treated samples have more genomic VDR binding sites than 
untreated samples (treated: 2,776; control: 623) and overlap 
with enhancer histone markers (such as in VDR and ALOX5) 
resulting in the upregulation of the expression of 226 genes, and 
downregulation of three genes (116). Furthermore, after treat-
ment with 1,25(OH)2D3 the cells showed a significant increase 
of intronic (treated: 36%; control: 26%) and intergenic (treated: 
28%; control: 10%) binding sites (116). Interestingly, more than 
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40% of VDR binding regions overlap with strong enhancer 
regions in LCL, which is disproportionally more than that in 
non-immune cell types (117). Similarly, after 1,25(OH)2D3 
treatment of THP-1 cells, a human monocytic leukemia cell 
line that resembles monocytes/macrophages, the VDR binding 
sites increased (treated: 1,820; control: 1,169) and shifted from 
the proximal transcription start site to distal regions (119). 
A comparison of multiple VDR ChIP-seq datasets from different 
cell types, including THP-1, LCLs (GM10855 and GM10861), 
LX2 (lung derived cell line), and LS180 (colon derived cell line), 
showed little overlap, suggesting a strong cell type specificity of 
VDR binding. For example, LPS-induced THP-1 cells, have 22% 
more VDR binding sites than that in the original THP-1 cells. 
Yet, they show more overlap of VDR binding regions compared 
with the overlap between monocyte and other different cell types 
(120). The overlap of VDR cistrome between two cell types with 
closer relationship is larger than overlap between cells with 
distant relationship: overlap between myeloid cells (monocyte/
DC1/DC2) > overlap between myeloid cells and B cells > over-
lap between myeloid cells and stellate cells (53). However, despite 
these discrepancies between cell lines, the characteristics of the 
genomic changes after 1.25(OH)2D3 engagement of VDR imply 
a shift from an induction of gene expression through promoter 
engagement to a binding to potential enhancer regions both in 
LCL and THP-1 cells.
The Association of Nuclear VDR Binding and MS
By combining MS transcriptome data with VDR ChIP-seq 
data, the association between the VDR binding regions and 
characteristic MS genes has been studied. For example, after 
comprehensively analyzing vitamin D ChIP-seq data in LCL 
and whole blood mRNA transcriptome from MS patients and 
healthy controls, VDR binding sites were found to be enriched in 
genes that were differentially expressed in different forms of MS, 
such as primary progressive MS, secondary progressive MS, and 
relapsing–remitting MS, compared with that in controls (116). 
Furthermore, MS risk SNPs, such as rs703842, that are reported 
as eQTL in immune cells, are associated with transcription level 
of VDR bound CYP27B1 (107).
Furthermore, genomic overlap and enrichment analysis 
pointed to disease risk SNP region that were enriched by VDR 
binding sites, and VDR binding sites with risk SNP located in. In 
CD4+ T cells, VDR-binding loci were enriched near SNP regions 
(100  kb around SNPs) that were associated with autoimmune 
diseases including MS and T-regulatory/T-helper cell functions 
(125). In LCL, VDR ChIP-seq data showed enrichment of VDR 
binding sites in GWAS identified intervals that were associated 
with multiple inflammatory diseases including MS, or vice versa 
autoimmune disease risk SNPs were found to overlap with VDR 
binding intervals (116). Furthermore, by supplementary anno-
tation with epigenetic chromatin states data from ENCODE, 
both VDR-SE (strong enhancer) overlap and VDR-AP (active 
promoter) overlap are more likely to be present within MS risk 
regions comparing to the rest of the genome in LCLs (117). In 
myeloid cells, MS risk alleles, from three MS GWASs (17, 18, 133), 
are enriched (p < 10−4, not corrected for multiple testing) in VDR 
binding peaks (53).
Potential Mechanisms of vDR involvement 
in the Determination of MS-Associated 
Cell Fate
As mentioned earlier, the explanation for the effect of genomic 
regions with functional genomic annotation, such as annotating 
MS risk SNP in non-coding region with ENCODE data men-
tioned earlier, is an important addition to functional experi-
mental studies. Functional experimental studies on causal 
SNP are mainly analyzing the potential interference between 
risk SNP alleles and gene expression or TF binding affinity 
using methods such as qPCR/microarray, Luciferase Reporter 
Assay or Electrophoretic Mobility Shift Assay. However, tra-
ditional experiments have some clear disadvantages, such as 
cumbersome, low-throughput methodology, hypothesis bias, 
or altered 3D structure of chromatin when using luciferase 
reporter. With the development of next-generation sequenc-
ing (NGS) and the dawn of the field of epigenetics, establishing 
annotation profiles has become easier. Especially, combined 
with NGS it was possible to define genomic SE structures 
and to identify their role in cell fate decisions, which made 
annotation more convincing and relevant. Below, we will 
discuss the definition of SEs and their association with the 
VDR and the role of VDR in dynamic chromatin landscape 
shaping processes.
Identification of Enhancer and SE Elements
Enhancers now can be identified by H3K4me1 (methylation of 
lysine 4 of histone 3), while active enhancers can be distinguished 
by H3K27ac (acetylation of lysine 27 of histone 3) and silent/
poised enhancers by H3K27me3 (trimethylation of lysine 27 of 
histone 3) (134). Therefore, a genome-wide enhancer landscape 
of active enhancers was identified using the ChIP-seq method 
(135, 136). And as the association of enhancer with master TF 
(such as T-bet), pervasive coregulators (such as CREB-binding 
protein/p300, BRD4, and MED1) and DNA accessibility [such 
as regions identified by DNase-seq, formaldehyde-assisted 
isolation of regulatory elements-seq (FAIRE-seq) and Assay 
for transposase-accessible chromatin using sequencing (ATAC-
seq)], they can also be used as an enhancer marker (31, 32, 
137–139). Originally, the SNP loci associated with the greatest 
impact on cell fate or phenotype were assumed to be in the coding 
region of functional genes or in the promoter sequence of key TF 
genes (140, 141). However, with the impact of enhancers on cell 
identity and differentiation coming increasingly into focus, many 
functionally important SNP sites were found to be located in or 
in the vicinity of enhancers (142, 143). The recent observation 
that the regulation of lineage determining TFs, signal-dependent 
TFs, mediators, and chromatin-modifying coregulators were all 
governed by clusters of enhancers in a close spatial arrangement 
has led to the definition of SEs, which show higher enrichment 
for selected enhancer markers (31–33, 139, 144). Indeed, more 
risk SNPs have been found to be associated with SE structures 
of specific cell types than with normal enhancers (33, 143, 145). 
For example, type 2 diabetes-associated risk SNPs are located in 
enhancer clusters which are specifically active in pancreatic islets 
(146). Importantly, TFs can regulate cell-specific genes indirectly 
FiGURe 1 | Vitamin D regulates the transcription of target genes. After binding its ligand 1,25(OH)2D3 and recruiting its partner retinoid X receptor (RXR), vitamin D 
receptor (VDR) enters the nucleus and binds to the transcription factor (TF) binding sites of target genes, where causal risk single-nucleotide polymorphism may be 
located. This induces transcription after the activation of other components of the transcription complex has been completed. A key enhancer can potentially be 
transcribed into a non-coding enhancer RNA, which regulates gene transcription or orchestrates cohesion-dependent looping to bring target gene promoter and 
enhancer region into a single-loop domain. The transcription activity of the whole domain is limited and regulated in a 3D loop isolated from other DNA regions by 
CCCTC-binding factor (CTCF) and cohesin (148), and some of CTCF overlap with binding of VDR (125, 126). Enhancers bound by VDR/RXR especially that in the 
so-called super-enhancers (SEs) or TF hotspot regions will recruit coregulators that shape chromosome landscapes and cooperate with other TFs. Other genes that 
are located in the 3D loop but outside the regulatory hub can also be transcribed but at lower rate. Outside the 3D loop, preoccupied VDR or RXR can be detected 
without vitamin D stimulation showing only low regulatory activity. Some preoccupied basal RXR binding sites can predict VDR binding sites following 1,25(OH)2D3 
stimulation and could represent storage regions for the VDR in the absence of 1,25(OH)2D3. After ligand binding, these “stored” VDR can shift to a DR3 motif in 
intronic and intergenic regions of regulated genes (120). However, the preoccupied VDR region with DR3 motif plays a master (persistent/mother) enhancer role, 
persist, and will promote the whole region activation and SE shaping. Secondary VDR binding region without DR3 motif (suggesting it binds DNA via interaction  
with other pioneer TFs or via non-classic unknown RXR/VDR motifs) will constitute subservient (secondary/daughter) enhancers around master enhancers in SE 
region (121, 150).
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via SE region in other key TF genes, such as the Bach2 gene in 
Th1/2/17 cells (32, 147). Different cytokine/cytokine receptor 
genes with SEs in different Th subsets (Th1/2/17) are all repressed 
by Bach2, whose gene also has an SE region in all these Th subsets, 
suggesting that SEs can shape a regulation network and that it will 
be possible to predict the role of TF genes in certain cell types 
(32, 147). Interestingly the CYP27B1 haplotype is located in an 
SE region in mouse Th cells (dbSUPER database) (31). On the 
other hand, enhancers and SEs can themselves serve as transcrip-
tion units and can generate non-coding and long non-coding 
enhancer RNAs. Their transcription is correlated with enhancer 
activities and also plays a regulatory role on the formation of 
enhancer–promoter loops and cell fate determination (112). 
Recently, one search identified a non-coding RNA, ThymoD, 
that was transcribed from the Bcl11b enhancer of an SE region. 
This RNA molecule can direct enhancer–promoter loop shaping, 
which further establishes T  cell identity and blocks lymphoid 
malignancy (148). As only <20% of putatively causal SNPs affect 
TF binding, there needs to be another mechanism how risk SNPs 
exert their biological function. The functional failure of enhancer 
RNA caused by risk SNP allelic variations could be a possible 
explanation (112).
Therefore, the fate of cells depends on chromatin modifications 
in cis-regulatory enhancer elements. The master TF are the major 
regulatory elements whereas SE regions and their modifications 
provide focal points on DNA sequences for those master TFs to 
act (149). After hormone or vitamin stimulation (such as estrogen 
or vitamin D) hormone ligand-induced SE regions are located 
around central enhancers with canonical hormone-specific 
regions (such as VDR DR3 elements or ERα dimer-specific 
elements). After ligand stimulation, subordinate enhancers 
would begin to shape the genomic environment around central 
enhancers together with motif enrichment of collaborating 
partners [such as Forkhead box protein A1 (FOXA1) or activator 
protein 1] (150). This is consistent with other research that shows 
that persistent VDR regions in THP-1 human monocytes show 
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highly conserved binding of DR3-type motifs with high affinity 
after ligand stimulation (121). These persistent primary VDR loci 
in the same TAD will affect chromatin accessibility for further 
PU.1 and VDR binding, which leads to a general cell activation, 
while transient primary VDR loci regulate specifically their 
immune associated genes. As we mentioned before, SE, as a key 
regulatory region, is of great use for identifying key genes in cell 
fate determining. However, as SE defined by different enhancer 
markers will lead to different key regions, the relationship 
between SEs shaped by environmental signal TF and SE shaped 
by key TFs is still unclear. For example, in murine embryonic 
stem cells (mESCs), SEs shaped by key TFs (OCT4, SOX2, and 
NANOG) are correlated with and provide a platform for signal 
TFs (STAT3, SMAD3, and TCF3), but in MCF-7 cells, ERα, and 
FOXA1-shaped distinct SE regions. Therefore, focusing on the 
effect of the modification of regulatory hubs in the presence of 
VDR can help our understanding of vitamin D’s effect on specific 
cell types (Figure 1), and the clarification of relationship between 
VDR and SEs in multiple immune cell types would further the 
understanding of MS pathogenesis.
The Hierarchical and Chronological Order of VDR 
and Other TFs Binding to Key Enhancers during  
Cell Differentiation
Recent immune cell plasticity research emphasized the impor-
tance of TFs that are dependent on environmental signals, such 
as VDR (vitamin D-dependent), SMAD3 (TGF-β-dependent), 
and STAT (cytokine dependent), which participate in the modi-
fication of enhancer landscapes and interact with master TFs, 
such as T-BET, PU.1 and OCT4. In macrophages and B  cells, 
the master TF PU.1 plays a pivotal role in shaping a cell-specific 
epigenetic genomic landscape to enable the subsequent binding 
of environmental signal-dependent TFs that directly regulate 
gene expression (151). In mESCs, myotubes and pro-B cells, cell 
type-specific master TFs such as OCT4, MYOD1, and PU.1 also 
modify the chromosome landscapes and direct TGF-β/SMAD3 
to bind different identity gene loci separately (152). Indeed, 
master TF-deficient cells show only limited impact on estab-
lishing the mature phenotype in CD4+ T  cells, and the pivotal 
factors that shape epigenetic genomic landscapes in T cells are 
still elusive. However, there are some clues. Signal-dependent 
TF, such as STATs, have an important role in chromosome 
modification during T cell differentiation. For example, STAT4 
promotes H3K4me3 modification on Th1 cell identity genes, and 
STAT6 modifies H3K27me3 in gene loci of Th2 cell identity genes 
(153). While the expression of master TF (e.g., T-bet) in signal-
dependent TF-deficient cells (e.g., STAT4-deficient cells) fails to 
recover enhancer landscape changes and consequently, the cell 
phenotype (e.g., Th1 cells) (123, 147, 152, 154, 155). In Th17 cells, 
BATF and IRF4, not Th17 master TF RORγt, cooperate to modify 
chromatin landscapes including genome-wide distribution of 
p300 allowing other factors such as STAT3 and RORγt to attach 
(123). In general, it becomes clear that an underlying epigenetic 
instability is an important principle in the cell fate determination 
and the observed plasticity of cell subsets (156). Environmental 
signal-dependent TF potentially play an equal role with master 
TF, which of them is the pioneer factor that opens the chromatin 
is still uncertain. Therefore, the role of VDR in cell fate deter-
mination although not clearly elucidated could be larger than 
expected.
It is noteworthy that TF binding is always dynamic and 
transient rather than stable which makes the molecular basis of 
differentiation even more complex. In some cases VDR can bind 
to positions before actual 1,25(OH)2D3 stimulation. After stimu-
lation, the VDR binding profile will shift to new positions (119). 
Finally, multiple factors can bind certain DNA regions in turn 
according to the dynamically changing epigenetic landscapes 
shaped by binding TFs. For instance, cyclical chromatin looping 
and TF binding of the regulatory region of p21 gene has been 
observed after stimulation with 1,25(OH)2D3 (157).
CONCLUSiON AND PeRSPeCTiveS
Overall, the role of the VDR cistrome in the epigenomic shap-
ing of the enhancer landscapes and cell type determination will 
affect the maturation and differentiation of immune cells that are 
involved in the pathogenesis of MS. We suggest that this may be 
a key to the explanation of the biological contribution of risk-
associated vitamin D SNPs, as well as environmental levels of 
vitamin D and MS risk.
In the future, we will benefit significantly from new tech-
nologies. High throughput methods, such as RNA-seq, ChIP-seq, 
updated ChIP-seq with higher resolution (ChIP-exo), chromatin 
interaction analysis by paired-end tag sequencing (ChIA-PET), 
high-resolution chromosome conformation capture (Hi-C) are 
providing a more complete and unbiased view of the TF cistrome 
and TF networks. Taken together with traditional experiments, 
high throughput methods and bioinformatics, great advance-
ments have been made in analyzing the regulation, interactions 
and functions of VDR and its ligands in immune cells. Further 
exploration will help to understand this highly dynamic and 
environmentally responsive network and answer the question 
how individual variations in environmental levels of vitamin D, 
genotypes, and risk alleles, in particular, influence or modulate 
outcomes in immune cell differentiation and predispose indi-
viduals to autoimmune diseases such as MS. MS epidemiology 
researchers can design clinical studies that include new data from 
NGS via increased coordination and collaboration with genom-
ics/epigenomics labs, which will potentially connect changes on 
MS risk genomic regions to clinical processes directly and lead to 
new insights in MS pathogenesis and new diagnosis/treatment 
targets.
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